Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma
US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...
Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...
Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...
Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round
Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million)...
ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development
ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100...
Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...
Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report
US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for...
Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment
The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...
Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...
BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences
Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based...
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...
Guangxi HSA Expands Coverage for Assisted Reproductive Medical Services Under BMI
The Healthcare Security Administration (HSA) bureau of the Guangxi Zhuang Autonomous Region has announced a...
Siyi Intelligence Secures Approval for Innovative Rehabilitation Robots in China
Shanghai-based Siyi Intelligence, a developer of soft rehabilitation robots, has announced that it has received...
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with...
Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform
Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...
Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor
Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...
Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment
Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...